Adjuvant therapy of resectable rectal cancer

Cancer Treatment Reviews

Volumn 28, Issue 4, 2002, Pages 181-188

  Minsky, Bruce D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Combined modality therapy; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; RALTITREXED; UFT;

ACUTE DISEASE; ANUS SPHINCTER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MULTIMODALITY CANCER THERAPY; OXYGENATION; PELVIS; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; RADIOSENSITIVITY; RECTUM CANCER; RECTUM SURGERY; REVIEW; STANDARD;

EID: 0036669123     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00037-3     Document Type: Article

References (81)

1. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. J Amer Med Assoc 1990; 264: 1444-1450.
2. Skibber JM, Hoff PM, Minsky BD, Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott, Williams and Wilkens, 2001; Cancer of the Rectum. pp. 1271-1318.
3. Bosset JF, Horiot JC, Hamers HP, Cionini L, Bartelink H, Caspers RJL, Untereiner M, Ciambelloti E, Pierart M, van Glabbeke M. Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol 2001; 61: 7-13.
4. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715.
5. Wolmark N, Weiand HS, Hyams DM, Colangelo L, Dimitrov N, Romond EH, Wexler M, Rager D, Cruz AB, Gordon PH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project protocol R-02. J Natl Cancer Inst 2000; 92: 388-396.
6. Tepper JE, O'Donnell MJ, Niedzwiecki D, Hollis DR, Benson III AB, Cummings B, Gunderson LL, Macdonald JS, Martenson Jr. JA, Mayer RJ. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control - final report of Intergroup 0114. J Clin Oncol 2002; 20(III): 1744-1750.
7. Minsky BD, Cohen AM, Enker WE, Kemeny N, Kelsen DP, Reichman B, Saltz L, Sigurdson E, Frankel J, Wiseberg J. Combined modality therapy of rectal cancer: decreased acute toxicity with the pre-operative approach. J Clin Oncol 1992; 10: 1218-1224.
8. Sauer R, Fietkau R, Wittekind C, Martus P, Rodel C, Hohenberger P, Jatzko G, Sabitzer H, Karstens JH, Becker HD, et al. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. Strahlenther Onkol 2001; 177:173-181.
9. Roh MS, Petrelli N, Weiand H, et al. Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). Proc ASCO 2001; 20: 123a [Abstract].
10. Botwood N, James R, Vernon C, et al. A phase I study of "Tomudex" (raltitrexed) with radiotherapy (RT) as adjuvant treatment in patients (pt) with operable rectal cancer. Proc ASCO 1998; 17: 277a [Abstract].
11. Fernandez-Martos C, Aparicio J, Bosch C, et al. Preoperative therapy (PT) with oral uracil and tegafur (UFT) and concomitant irradiation (RT) in operable rectal cancer (RC). Preliminary results of a multicenter phase II study. Proc ASCO 2001; 20: 148a [Abstract].
12. Valentini V, Morganti AG, Luzi S, et al. Chemoradiation with raltitrexed (Tomudex) and oxaliplatin in preoperative treatment of stage II/III resectable rectal cancer: a dose finding study. Proc ASCO 2001; 20: 131a [Abstract].
13. Freyer G, Bossard N, Romestaing P, Mornex F, Chapet O, Trillet-Lenoir V, Gerard JP. Addition of oxaliplatin to continuous infusion fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 2001; 19: 2433-2438.
14. Klautke G, Kirchner R, Hopt U, et al. Continuous infusion of 5-FU and weekly irinotecan with concurrent radiotherapy as neoadjuvant treatment for locally advanced or recurrent rectal cancer. Proc ASCO 2001; 20: 140a [Abstract].
15. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 1512-1521.
16. Dunst J, Reese T, Frings S. Phase I study of capecitabine combined with simultaneous radiotherapy in rectal cancer. Proc ASCO 2001; 20: 149a [Abstract].
17. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer. Do all patients require post- operative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999; 42:167-173.
18. Merchant NB, Guillem JG, Paty PB, Enker WE, Minsky BD, Quan SHQ, Wong D, Cohen AM. T3NO rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999; 3: 642-647.
19. Minsky BD. Multidisciplinary management of resectable rectal cancer. Oncology 1996; 10: 1701-1714.
20. Camma C, Giunta M, Fiorica F, Pagliaro, L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Amer Med Assoc 2000; 284: 1008-1015.
21. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 2001; 358: 1291-1304.
22. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-987.
23. Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJT, Pahlman L, Glimelius B, van Krieken JHJM, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646.
24. van de Velde CJH. Preoperative radiotherapy and TME-surgery for rectal cancer: detailed analysis in relation to quality control in a randomized trial. Proc ASCO 2002; 21: 127a [Abstract].
25. Marijnen CAM, Kapiteijn E, van de Velde CJH, Martijn H, Steup WH, Wiggers T, Kranenbarg EK, Leer JWH. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2002; 20: 817-825.
26. Graf W, Dahlberg M, Osman MM, Holmberg L, Pahlman L, Glimelius B. Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol 1997; 43: 133-137.
27. Marijnen CAM, Nagtegaal ID, Kranenbarg EK, Hermans J, van de Velde CJH, Leer JWH, van Krieken JHJM. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19: 1976-1984.
28. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P, Gerard JP. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396-2402.
29. Sauer R, Fietkau R, Martus P, et al. Adjuvant and neoadjuvant radiochernotherapy for advanced rectal cancer - first results of the German multicenter phase-III-trial. Int J Radial Oncol Biol Phys 2000; 48: 119 [Abstract].
30. Wagman R, Minsky BD, Cohen AM, Guillem JG, Paty PB. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998; 42: 51-57.
31. Rouanet P, Saint Aubert B, Lemanski C, Senesse P, Gourgou S, Quenet F, Ychou M, Kramar A, Dubois JB. Restorative and nonrestorative surgery for low rectal cancer after high dose radiation. Long term oncologic and functional results. Dis Colon Rectum 2002; 45: 305-315.
32. Hyams DM, Mamounas EP, Petrelli N, Rockette H, Jones J, Wieand S, Deutsch M, Wickerharn L, Fisher B, Wolmark N. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum. A progress report of the National Surgical Adjuvant Breast and Bowel Project protocol R0-3. Dis Colon Rectum 1997; 40: 131-139.
33. Valentini V, Coco C, Cellini N, Genovesi D, Mantini G, Barbaro B, Cogliandolo S, Mattana C, Ambesi-Impiombata F, Tedesco M, et al. Preoperative chemoradiation for extra-peritoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radial Oncol Biol Phys 1998; 40:1067-1075.
34. Grann A, Feng C, Wong D, et al. Pre-op combined modality therapy (CMT) for uT3 rectal cancer. Proc ASCO 2000; 19: 249a [Abstract].
35. Maghfoor I, Wilkes J, Kuvshinoff B, et al. Neoadjuvant chemoradiotherapy with sphincter-sparing surgery for low lying rectal cancer. Proc ASCO 1997; 16: 274 [Abstract].
36. Grumann MM, Noack EM, Hoffman IA, Schlag PM. Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. Ann Surg 2001; 233: 149-156.
37. Kollmorgen CF, Meagher AP, Pemberton JH, Martenson JA, Ilstrup DM. The long term effect of adjuvant postoperative chemoradiotherapy for rectal cancer on bowel function. Ann Surg 1994; 220: 676-682.
38. Onaitis MW, Noone RB, Fields R, Hurwitz HI, Morse M, Jowell P, McGrath K, Lee C, Anscher MS, Clary BM, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 2001; 8: 801-806.
39. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001; 24: 107 112.
40. Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara PF, McGrath P, Marks GM. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced /recurrent rectal cancers. Int J Radiat Oncol Biol Phys 2000; 48: 1075-1080.
41. Read TE, Ogunbiyi OA, Fleshman JW, Birnbaum EH, Fry RD, Myerson RJ, Kodner IJ. Neoadjuvant external beam radiation and proctectomy for adenocarcinoma of the rectum. Dis Colon Rectum 2001; 44: 1778-1790.
42. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002; 194: 131-136.
43. Luna-Perez P, Segura J, Alvarado I, Labastida S, Santiago-Payan H, Quintero A. Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 2000; 7: 727-731.
44. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez-Monge R, Salgado E, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19: 1779-1786.
45. Esposito G, Pucciarelli S, Alaggio R, Giacomelli L, Marchiori E, Iaderosa GA, Friso ML, Toppan P, Chieco-Bianchi L, Lise M. p27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 2001; 8: 311-318.
46. Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B. Can p53 alterations be used to predict tumor response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?. Radiother Oncol 2000; 56: 239-244.
47. Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kuhrer I, Kappel S, Wrba F, Horvath M, et al. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 2002; 235: 493-498.
48. Schwander O, Bruce HP, Broll R. p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance. Int J Colorectal Dis 2002; 17: 11-19.
49. Adell GCE, Zhang H, Evertsson S, Sun XF, Stal OHG, Nordenskjold BA. Apoptosis in rectal cancer. Prognosis and recurrence after preoperative radiotherapy. Cancer 2001; 91: 1870-1875.
50. Rodel C, Grabenbauer GG, Papadopoulos T, Bigalke M, Gunther K, Schick C, Peters A, Sauer R, Rodel F. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2002; 52: 294-303.
51. Adell G, Zhang H, Jansson A, Sun XF, Stal O, Nordenskjold B. Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2001; 50: 659-663.
52. Habr-Gama A, Santinho B, de Souza PM, Ribeiro U, Nadalin W, Gansl R, H.S.e Sousa A, Campos FG, Gama-Rodrigues J. Low rectal cancer. Impact of radiation and chemotherapy on surgical treatment. Dis. Colon Rectum 1998; 41: 1087-1096.
53. Barbaro B, Schulsinger A, Valentini V, Marano P, Rotman M. The accuracy of transrectal ultrasound in predicting the pathological stage of low-lying rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 1999; 43: 1043-1047.
54. Gavioli M, Bagni A, Piccagli I, Fundaro S, Natalini G. Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer. Dis Colon Rectum 2000; 43: 1075-1083.
55. Guillem JG, Puig-La Calle J, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub M, Klimstra D, Mazumdar M, Paty PB, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000; 43: 18 24.
56. Guillem JG, Moore HG, Akhurst T. Prospective evaluation of the prognostic significance of FDG-PET assessment of rectal cancer response to preoperative chemoradiation. Proc ASCO 2002; 21: 145a [Abstract].
57. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-460.
58. Leong APK. Selective total mesorectal excision for rectal cancer. Dis Colon Rectum 2000; 43: 1237-1240.
59. Haas-Kock DFM, Baeten CGMI, Jager JJ, Langendijk JA, Schouten LJ, Volovics A, Arends JW. Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg 1996; 83: 781-785.
60. Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181: 335 345.
61. Arenas RB, Fichera A, Mhoon D, Michelassi F. Total mesenteric excision in the surgical treatment of rectal cancer. A prospective study. Arch Surg 1998; 133: 608-612.
62. Havenga K, Enker WE, Norstein J, Moriya Y, Heald RJ, van Houwelingen JC, van de Velde CJH. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol 1999; 25: 368-374.
63. Aitken RJ. Mesorectal excision for rectal cancer. Br J Surg 1996; 83: 214 216.
64. Carlsen E, Schlichting E, Guldvog I, Johnson E, Heald RJ. Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg 1998; 85: 526-529.
65. Poon RTP, Chu KW, Ho JWC, Chan CW, Law WL, Wong J. Prospective evaluation of selective defunctioning stoma for low anterior resection with total mesorectal excision. World J Surg 1999; 23: 463-468.
66. Dahlberg M, Glimelius B, Pahlman L. Changing strategy for rectal cancer is associated with improved outcome. Br J Surg 1999; 86: 379-384.
67. Cox JD, Guse C, Asbell S, Rubin P, Sause WT. Tolerance of pelvic normal tissues to hyperfractionated. radiation therapy: results of protocol 83-08 of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1988; 15: 1331-1336.
68. Coucke PA, Cuttat JF, Mirimanoff RO. Adjuvant postoperative accelerated hyperfractionated radiotherapy in rectal cancer: a feasibility study. Int J Radiat Oncol Biol Phys 1993; 27: 885-889.
69. Coucke PA, Sartorelli B, Cuttat JF, Jeanneret W, Gillet M, Mirimanoff RO. The rationale to switch from postoperative hyperfractionated accelerated radiotherapy to preoperative hyperfractionated accelerated radiotherapy in rectal cancer. Int J Radiat Oncol Biol Phys 1995; 32: 181-188.
70. Stupp R, Matter M, Volter V, et al. Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal cancer (LARC): a phase I study. Int J Radiat Oncol Biol Phys 2001; 51: 11 [Abstract].
71. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley SA, Ellis LM, Vauthey JN, Lenzi R, Lynch P, et al. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2000; 47: 713-718.
72. Movsas B, Hanlon A, Lanciano R, Scher RM, Weiner LM, Sigurdson ER, Hoffman J, Eisenberg BL, Cooper HS, Provins S, et al. Phase I dose escalating trial of hyperfractionated preoperative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 1998; 42: 43-50.
73. Diratzouian H, Movsas B, Hanlon AL, et al. Phase II trial of preoperative chemoradiation with a hyperfractionated RT boost in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2001; 51: 10 [Abstract].
74. Myerson RJ, Valentini V, Birnbaum EH, Cellini N, Coco C, Fleshman JW, Gambacorta. MA, Genovesi D, Kodner Ij, Picus J, et al. A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys 2001; 50: 1299-1308.
75. Tait DM, Nahum AE, Meyer LC, Law M, Dearnaley DP, Horwich A, Mayles WP, Yarnold JR. Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother Oncol 1997; 42: 121-136.
76. Shank B, LoSasso T, Brewster L, Burman C, Cheng E, Chu JCH, Drzymala RE, Manolis J, Pilepich MV, Solin LJ, et al. Three-dimensional treatment planning for post-operative treatment of rectal carcinoma. Int J Radial Oncol Biol Phys 1991; 21: 253-265.
77. Tatsuzaki H, Urie MM, Willett CG. 3-D comparative study of proton vs. x-ray radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 1991; 22: 369-374.
78. Duncan W, Arnott SJ, Jack WJL, Orr JA, Kerr GR, Williams JR. Results of two randomized trials of neutron therapy in rectal adenocarcinoma. Radiother Oncol 1987; 8: 191-198.
79. Anscher MS, Lee C, Hurwitz HI, Tyler DS, Prosnitz LR, Jowell P, Rosner G, Samulski T, Dewhirst MW. A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. Int J Radiat Oncol Biol Phys 2000; 47: 719-724.
80. Rau B, Wust P, Tilly W, Gellermann J, Harder C, Riess H, Budach V, Felix R, Schlag PM. Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters. Int J Radiat Oncol Biol Phys 2000; 48: 381 391.
81. van der Zee J, Gonzalez DG, van Rhoon GC, van Dijk JD, Putten WLJ, Hart AAM. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumors: a prospective, randomised, multicenter trial. Lancet 2000; 355:1119-1125.